Trial Profile
A prospective observational study to compare the efficiency of three types of erythropoiesis-stimulating agents (ESA) epoetin alfa (Eprex®), epoetin beta (NeoRecormon®) and darbepoetin (Aranesp®) vs control in anemic patients with lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Feb 2016
Price :
$35
*
At a glance
- Drugs Darbepoetin alfa (Primary) ; Epoetin alfa (Primary) ; Epoetin beta (Primary)
- Indications Chemotherapy-induced anaemia
- Focus Therapeutic Use
- 02 Feb 2016 New trial record